Biotest AG acquires ninth plasma collection center in Germany
- 100% subsidiary Plasma Service Europe takes over plasma centre in Hanover
- In the future, 20 plasma collection centres in Europe to ensure long-term plasma supply
Dreieich, 15 November 2018. Plasma Service Europe GmbH, a 100% subsidiary of Biotest AG, has acquired a plasmapheresis centre in Hanover, Germany. The closing of the transaction is expected in the first quarter 2019. This purchase is a step towards better plasma self-sufficiency.
"Strategically, we strive to achieve balanced growth in plasma supply across all countries in Europe. This acquisition will enable us to further increase our high level of supply with German plasma.", stated Dr Martin Reinecke, Senior Vice President of Global Plasma Alliances and Protein Supply at Biotest AG.
The collected plasma will be processed only by Biotest AG at Dreieich, Germany. Regular audits ensure that strict legal and internal quality requirements are met.
About human blood plasma
Human blood plasma is a raw material used to produce plasma derived products, which are used to treat various illnesses of the immune system, the blood system, as well as in emergency medicine. Biotest ranks as one of the world's sixth largest plasma protein product manufacturing groups. Biotest is one of the world's six largest manufacturers of plasma protein products.
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition, Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies. Biotest has more than 1,600 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.
Dr Monika Buttkereit
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.
15.11.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de